| OPKO Health, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120015921 | PHARMACEUTICAL FORMULATIONS:SALTS OF 8-[1-3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXYMETHYL]-8-PHENYL-1,7-DIAZA-SP- IRO[4.5]DECAN-2-ONE AND TREATMENT METHODS USING THE SAME - Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 01-19-2012 |
| 20110245197 | HYPERSULFATED GLUCOPYRANOSIDES - Hypersulfated disaccharides, preferably octasulfated sucrose, with utility in asthma or asthma related disorders are disclosed. The compounds may optionally be formulated with pharmaceutically acceptable excipients or delivery agents. The delivery agents are selected from the group consisting of natural or synthetic polymers, aerosols or other vehicles that facilitate the delivery or administration of the drug. The hypersulfated disaccharides are made from carbohydrate starting materials. Ion exchange or other suitable synthetic processes may be utilized to prepare the pharmaceuticals. The hypersulfated disaccharides are useful as anti-inflammatory agents. | 10-06-2011 |
| 20110136757 | HYPERSULFATED DISACCHARIDE FORMULATIONS - Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The compounds are formulated with agents that enhance the oral delivery of the hypersulfated disaccharides. The delivery agents are selected from the group consisting of natural or synthetic polymers having ionic side chains as well as other compounds or types of compounds that improve the bioavailability of the disaccharides relative to delivery of the drug without such agents. The hypersulfated disaccharides are made from heparin or salts thereof. | 06-09-2011 |
| 20110098468 | NK1 ANTAGONISTS | 04-28-2011 |
| 20110038925 | INTRAVENOUS FORMULATIONS OF NEUROKININ-1 ANTAGONISTS - Pharmaceutical compositions for intravenous administration comprising the compound of Formula I | 02-17-2011 |
| 20100190759 | NK 1 ANTAGONISTS - A compound having the general structure shown in Formula I: | 07-29-2010 |
